Cargando…

Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST

BACKGROUND: The Response Evaluation Criteria in Solid Tumors (RECIST) are the current standard for evaluating disease progression or therapy response in patients with solid tumors. RECIST 1.1 calls for axial, longest-diameter (or perpendicular short axis of lymph nodes) measurements of a maximum of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fenerty, Kathleen E., Folio, Les R., Patronas, Nicholas J., Marté, Jennifer L., Gulley, James L., Heery, Christopher R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995658/ https://www.ncbi.nlm.nih.gov/pubmed/27553491 http://dx.doi.org/10.1186/s12885-016-2699-x

Ejemplares similares

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Chordoma: The Quest for Better Treatment Options
por: Heery, Christopher R.
Publicado: (2016)

Erratum to: Chordoma: The Quest for Better Treatment Options
por: Heery, Christopher R.
Publicado: (2016)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
por: van Persijn van Meerten, Els L., et al.
Publicado: (2009)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma
por: DeMaria, Peter Joseph, et al.
Publicado: (2021)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
por: Traylor, Jeffrey I., et al.
Publicado: (2021)

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)

Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria
por: Kidd, Andrew C, et al.
Publicado: (2022)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report
por: Pastor, Danielle M., et al.
Publicado: (2020)

RECIST Applied to Realistic Tumor Models
por: Levine, Zachary H., et al.
Publicado: (2011)

iRECIST: how to do it
por: Persigehl, Thorsten, et al.
Publicado: (2020)

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
por: Choi, Hyun Chang, et al.
Publicado: (2015)

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Imaging tumour response: beyond RECIST
por: Koh, Dow-Mu
Publicado: (2014)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
por: Mulkey, Flora, et al.
Publicado: (2020)

The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment
por: Zhou, Ting, et al.
Publicado: (2015)

Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
por: Vrankar, Martina, et al.
Publicado: (2018)

Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence
por: Kim, Nari, et al.
Publicado: (2022)

The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies
por: Xu, Jiuhui, et al.
Publicado: (2023)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

A Letter in Support of Real-World RECIST
por: Gajra, Ajeet, et al.
Publicado: (2020)

Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
por: Singh, Harpreet, et al.
Publicado: (2014)

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
por: Madan, Ravi A, et al.
Publicado: (2012)

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
por: Madan, Ravi A, et al.
Publicado: (2014)

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group
por: Stacchiotti, S., et al.
Publicado: (2017)

Improved Semantic Segmentation of Tuberculosis—Consistent Findings in Chest X-rays Using Augmented Training of Modality-Specific U-Net Models with Weak Localizations
por: Rajaraman, Sivaramakrishnan, et al.
Publicado: (2021)

Chordoma
por: De, M. N., et al.
Publicado: (1939)

Chordoma
por: Harvey, W. F., et al.
Publicado: (1941)

A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial()
por: Malarkey, Molly, et al.
Publicado: (2023)

Autophagic Markers in Chordomas: Immunohistochemical Analysis and Comparison with the Immune Microenvironment of Chordoma Tissues
por: Karpathiou, Georgia, et al.
Publicado: (2021)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
por: Grenga, Italia, et al.
Publicado: (2013)

Imaging beyond RECIST: CT and MRI in molecular therapies
por: Diederich, Stefan
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_iqc06hfcokpk5usvda4i52vbeg